About Eidos Therapeutics & BridgeBio Pharma
Eidos Therapeutics, an affiliate of BridgeBio Pharma, is a Phase 3 developmental-stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. We seek to treat this well-defined family of diseases at their collective source by stabilizing TTR. Our investigational product, acoramidis (AG10), is an orally administered small molecule designed to potently stabilize TTR, a potentially best-in-class treatment aiming to halt the progression of ATTR diseases.
BridgeBio is a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. We bridge the gap between remarkable advancements in genetic science in academic institutions and the delivery of meaningful medicines to patients. Founded in 2015, the company has built a portfolio of 30+ drug development programs ranging from preclinical to late-stage development in multiple therapeutic areas including genetic dermatology, precision oncology, cardiology, endocrinology, neurology, pulmonology, and renal disease, with two approved drugs.
Our focus on scientific excellence and rapid execution aims to translate today’s discoveries into tomorrow’s medicines. We have U.S. offices in San Francisco, Palo Alto, and Raleigh, with small satellites in other parts of the country. We also have international offices in Montreal, Canada, and Zurich, Switzerland, and are expanding across Europe.
To learn more about our story and company culture, visit us at eidostx.com/ | https://bridgebio.com
Who You Are
As a Director/Sr. Director, Clinical Development, this candidate must have an MD (or MD equivalent) and advanced education and/or training in related scientific disciplines (e.g., basic science, biostatistics, public health, etc.). The candidate must work cross-functionally to develop strong relationships with key stakeholders within Clinical Development, Clinical Operations, Regulatory Affairs, Pharmacovigilance, Medical Affairs, and Commercial colleagues to support ongoing clinical trials and the lifecycle of the drug candidate. Being a Director/Sr. Director, this person will also support the medical monitoring of ongoing trials and medical/clinical team interactions with Key Opinion Leaders (KOLs), principal investigators (PIs), and study sites.
Responsibilities
- Support medical and clinical team in medical monitoring for transthyretin amyloidosis clinical studies
- Represent the medical team in clinical study team meetings, contributing medical/scientific knowledge to cross‐functional teams; liaise with other departments for data review in clinical and safety databases
- Cultivate relationships with investigative sites, clinical consultants, PIs and KOLs
- Provide medical support for the preparation of clinical protocols and protocol amendments as well as clinical sections of regulatory documents
- Provide support and leadership in scientific literature search, abstracts, manuscripts, posters, presentations preparation, Advisory Board meetings, and trainings
- Help ensure Clinical Study Team compliance with FDA, EMEA, ICH, GCP guidelines, and internal SOPs
- May travel up to 20% domestically and internationally for scientific meetings, Advisory Boards, other study-related activities, etc.
No matter your role at BridgeBio, successful team members are:
- Patient Champions, who put patients first and uphold strict ethical standards
- Entrepreneurial Operators, who drive toward practical solutions and have an ownership mindset
- Truth Seekers, who are detailed, rational, and humble problem solvers
- Individuals Who Inspire Excellence in themselves and those around them
- High-quality executors, who execute against goals and milestones with quality, precision, and speed
Education, Experience & Skills Requirements
- Trained MD, MD-PhD, or PhD
- Advanced education and/or training in related scientific disciplines (e.g., basic science, biostatistics, public health, etc.)
- 7+ years of experience in drug development, either within the industry or as a clinical investigator/physician-scientist in academia, or equivalent experience
- Experience in the rare disease field and/or cardiology or neurology
- Understanding of the drug development process and study conduct
- Strong work ethic
- Excellent English scientific writing skills
- Exceptional teamwork skills
- Good knowledge of GCP
- Strong interpersonal and leadership skills
- Ability to work independently in a fast-paced environment
- Travel – approximately 20% total time will be used for travel
What We Offer
- Patient Days, where we are fortunate to hear directly from individuals living with the conditions we are seeking to impact throughout the year and learn how we can improve our efforts
- A culture inspired by our values: put patients first, think independently, be radically transparent, every minute counts, and let the science speak
- An unyielding commitment to always putting patients first. Learn more about how we do this here
- A de-centralized model that enables our program teams to focus on advancing science and helping patients. Our affiliate structure is designed to eliminate bureaucracy and put decision-making power in the hands of those closest to the science
- A place where you own the vision – both for your program and your own career path
- A collaborative, fast-paced, data-driven environment where we inspire ourselves and each other to always perform at the top of our game
- Access to learning and development resources to help you get in the best professional shape of your life
- Robust and market-competitive compensation & benefits package (Base, Performance Bonus, Equity, health, welfare & retirement programs)
- Flexible PTO
- Rapid career advancement for strong performers
- Potential ability to work on multiple BridgeBio Pharma programs across multiple therapeutic areas over time
- Partnerships with leading institutions
- Commitment to Diversity, Equity & Inclusion